Peptide Legalization Looms: A $3B Gray Market Prepares to Go Mainstream

An FDA advisory panel convening Thursday in Maryland is expected to recommend legal commercial production of up to seven peptides — a decision that could transform a thriving but legally murky gray market into a regulated, mainstream industry. Compounding pharmacies, telehealth startups, and longevity entrepreneurs are descending on the agency's campus en masse, with Shaun Noorian, founder and CEO of Empower Pharmacy — one of the country's largest compounding pharmacies — saying he 'wouldn't miss it for the world.' The Alliance for Pharmacy Compounding's CEO Scott Brunner is predicting a 'circus' atmosphere, with hundreds of industry players flying in.

The peptides under review are currently only legal to produce for research purposes, yet that loophole has fueled an estimated $3 billion gray market operating almost entirely without regulatory oversight. Injectables like BPC-157 — hugely popular online for purported tendon, ligament, and muscle healing — and TB-500, promoted for reducing inflammation and accelerating wound recovery, are at the center of the discussion. Scientific data on their safety and efficacy remains sparse, and the market is riddled with sketchy, unregulated sellers. Despite this, the user base spans Silicon Valley tech workers, longevity-focused physicians, and MAHA wellness enthusiasts.

The cultural momentum behind peptides is significant. Health and Human Services Secretary Robert F. Kennedy Jr. publicly declared himself a 'big fan of peptides' during a February appearance on Joe Rogan's podcast. Wellness influencers routinely promote 'peptide stacks' for sleep, recovery, and performance online. Michelle Davey, founder and CEO of telehealth company Wheel, compared the emerging legal landscape to the supplement industry's early days and predicted at least six months of 'Wild West' conditions following any approval.

The stakes are enormous for the compounding pharmacy and telehealth sectors. Legal status would allow regulated production and distribution at scale — a massive commercial opportunity for companies like Empower Pharmacy that have been positioning themselves ahead of the ruling. The panel's recommendations won't immediately create law, but they would signal a clear regulatory pathway and likely trigger a rapid buildout of supply chains, prescriber networks, and consumer marketing infrastructure.